How 42 CFR Part 2 changes affect OTPs – methadone and PDMPs.

H. Westley Clark, M.D., J.D., is the former director of the Center for Substance Abuse Treatment (CSAT) at the Substance Abuse and Mental Health Services Administration (SAMHSA), the federal agency that has proposed to amend 42 CFR Part 2, the regulation protecting the confidentiality of alcohol and drug abuse treatment patient records. In a massive notice of proposed rulemaking (NPRM) published in 2019, SAMHSA proposed to remove the ban against giving opioid treatment program (OTP) patient data — methadone being the key medication — to prescription drug monitoring programs (PDMPs). That ban was instituted by Clark himself when, as CSAT director, he issued a "Dear Colleague Letter" to OTPs telling them they should not give patient medication data to the PDMP, but rather should check the PDMP to see what medications their patients are on. The rationale for the letter was the same as the rationale for opposition to SAMHSA's NPRM: Patients would not want to go to treatment if they knew their methadone information could be shared without their consent. [ABSTRACT FROM AUTHOR]

Copyright of Alcoholism & Drug Abuse Weekly is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)